Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Nivolumab in Advanced Cancer
NCT03396211Phase 1Completed
- Sponsor
- Elevar Therapeutics
- Start
- Dec 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in solid tumor, sponsored by Elevar Therapeutics. Primary endpoints: Treatment Emergent Adverse Events, Objective Response Rate and 5 more. Started Dec 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03396211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396211.